Volume 12 Issue 2, May 2018

Targeting a largely unmet and potentially billion-dollar market, SnooZeal is developing a clinically proven daytime treatment for snoring and sleep apnea.

With its innovative bone graft scaffold, GreenBone Ortho srl is well on its way to becoming a worldwide leader in bone regeneration.

Pacific Edge’s state-of-the-art suite of bladder cancer detection and management tests are noninvasive, highly effective, and more accurate than other urine-based cancer diagnostic tests, and are now being adopted into the standard of care.

Andarix Pharmaceuticals is a clinical-stage company that develops highly specific radiolabeled peptides for targeted radiotherapy and diagnostic imaging in cancer.

Arquer Diagnostics is developing a series of innovative, non-invasive tests for cancer and recently launched ADXBLADDER, a reliable urine test for bladder cancer.

Parkway Pantai, one of Asia’s largest private healthcare providers, has brought precision medicine into its integrated suite of healthcare services.

Karius has developed a cell-free-DNA-based diagnostic test capable of identifying bacteria, mycobacteria, DNA viruses, fungi and protozoa in the blood down to the species level, thereby rapidly improving the diagnosis of infectious diseases.

SkylineDx is using its expertise to bridge the gap between novel gene expression signatures and commercially available diagnostic products with high clinical utility.